TriangleDT2216 (NCT06964009)
DT2216 trial for Platinum-Resistant Ovarian Cancer (NCT06964009). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for platinum-resistant ovarian cancer that has come back, in adults.
The idea: pair a protein degrader with chemotherapy. DT2216 is designed to break down BCL-XL, a protein that helps protect cancer cells from cell death. It is given by vein with weekly paclitaxel. Treatment runs in 28 day cycles, with imaging every two cycles.
This phase 1 study looks for the highest dose that can be given safely, and plans 30 patients. At Dana-Farber Cancer Institute in Boston, Elizabeth Stover leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.